| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVIR | Common Stock | Purchase | $47.9K | +15K | +3.32% | $3.19 | 467K | Jan 15, 2025 | Direct | F1, F2 |
| transaction | AVIR | Common Stock | Purchase | $33.6K | +10K | +2.14% | $3.36 | 477K | Jan 16, 2025 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |